ESOC 2024 | ESOC 2024 highlights: tenecteplase trials and decompressive hemicraniectomy for deep ICH

Aristeidis Katsanos, MD, McMaster University, Hamilton, Ontario, Canada, comments on key updates from the 10th European Stroke Organisation Conference (ESOC) 2024, highlighting new evidence for the use of tenecteplase over alteplase for intravenous thrombolysis and the SWITCH trial which suggested the benefit of decompressive surgery plus optimal medical treatment over optimal medical treatment alone for patients with severe deep intracerebral hemorrhage. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.